Lonza Group AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other
pharmaceutical manufacturers in Europe:
sales of 4.53 billion Euro [US$5.14 billion]
of which 100%
(258.45 billion Russian Rubles [US$3.84 billion]
of which 78%
was Distribution), and
Stada Arzneimittel AG
based in Germany
(2.31 billion Euro [US$2.63 billion]
of which 59%
During the year ended December of 2017, sales at
Lonza Group AG were 5.11 billion Swiss Francs (US$5.14 billion).
increase of 23.5%
versus 2016, when the company's sales were 4.13 billion Swiss Francs.
This was the fourth straight year of sales growth at Lonza Group AG.
Sales of Eliminations saw an increase
15.2% in 2017, from
33.00 million Swiss Francs to 38.00 million Swiss Francs.